Thiazolidinediones: Metabolic actions in vitro

Diabetologia

Volumn 45, Issue 9, 2002, Pages 1211-1223

  Furnsinn C ^a   Waldhausl W ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adipose tissue; In vitro; Liver; Peroxisome proliferator activated receptor ; Skeletal muscle; Thiazolidinedione

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; FATTY ACID; GLUCOSE; NC 2100; NETOGLITAZONE; OXADIAZOLE DERIVATIVE; OXADIAZOLIDINEDIONE; PAT 5A; PEPTIDE HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REGLITAZAR; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; YM 440;

ADIPOCYTE; ADIPOSE TISSUE; CELL DIFFERENTIATION; CELL ISOLATION; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; GLUCOSE; HOMEOSTASIS; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0036381966     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-0899-1     Document Type: Review

References (153)

1. Watkins PB, Withcomb RW (1997) Hepatic dysfunction associated with troglitazone. N Engl J Med 338: 916-917
2. Kohlroser J, Mathei J, Reichheld J, Banner BF, Bonkovsky HL (2000) Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 95: 272-276
3. Gillies PS, Dunn CJ (2000) Pioglitazone. Drugs 60: 333-343
4. Lenhard MJ, Funk WB (2001) Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis. Diabetes Care 24: 168-169
5. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H (1988) Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549-1558
6. Hofmann C, Lorenz K, Colca JR (1991) Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 129: 1915-1925
7. Ye J-M, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW (2001) Peroxisome-proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats. Diabetes 50: 411-417
8. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW (1994) A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 43: 1203-1210
9. Lee M-K, Miles DG, Khourshed M, Gao K-M, Moossa AR, Olefsky JM (1994) Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43: 1435-1439
10. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15: 193-203
11. Bowen L, Stein PP, Stevenson R, Shulman GI (1991) The effect of CP 86,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 40: 1025-1030
12. Inzucchi SE, Maggs DG, Spollett GR et al. (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338: 867-872
13. Kraegen EW, James DE, Jenkins AB, Chisholm DJ, Storlien LH (1989) A potent effect of ciglitazone on muscle insulin resistance induced by high fat feeding of rats. Metabolism 38: 1089-1093
14. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J (1994) Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331: 1188-1193
15. Maggs DG, Buchanan TA, Burant CF et al. (1998) Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128: 176-185
16. Fürnsinn C, Brunmair B, Meyer M et al. (1999) Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism. Br J Pharmacol 128: 1141-1148
17. Zierath JR, Ryder JW, Doebber T et al. (1998) Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action. Endocrinology 139: 5034-5041
18. Sreenan S, Keck S, Fuller T, Cockburn B, Burant CF (1999) Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. Am J Physiol 276: E1119-E1129
19. Kanoh Y, Bandyopadhyay G, Sajan MP, Standaert ML, Farese RV (2000) Thiazolidinedione treatment enhances insulin effects on protein kinase C-/activation and glucose transport in adipocytes of nondiabetic and Goto-Kakizaki type II diabetic rats. J Biol Chem 275: 16690-16696
20. Baron AD, Brechtel G, Wallace P, Edelman SV (1988) Rates and tissue sites of non-insulin and insulin-mediated glucose uptake in humans. Am J Physiol 255: E769-E774
21. DeFronzo RA (1988) The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667-687
22. Olefsky JM (2000) Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest 106: 467-472
23. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA (1991) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956
24. Ibrahimi A, Teboul L, Gaillard D et al. (1994) Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 46: 1070-1076
25. Auboeuf D, Rieusset J, Fajas L et al. (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans. No alteration in adipose tissue of obese and NIDDM patients. Diabetes 46: 1319-1327
26. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8: 1224-1234
27. Fajas L, Auboeuf D, Raspe E et al. (1997) The organization, promotor analysis, and expression of the human PPARγ gene. J Biol Chem 272: 18779-18789
28. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771-774
29. Tontonoz P, Graves RA, Budavari AI et al. (1994) Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ and RXRα. Nucleic Acids Res 22: 5628-5634
30. Nolte RT, Wisley GB, Westin S et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395: 137-143
31. Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung L (1996) Nuclear receptor coactivators and corepressors. Mol Endocrinol 10: 1167-1177
32. Schoonjans K, Staels B, Auwerx J (1996) Role of the peroxisome proliferator-activated receptors (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 907-925
33. Tontonoz P, Hu E, Spiegelman BM (1995) Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ. Curr Opin Genet Dev 5: 571-576
34. Lowell BB (1999) PPARγ: An essential regulator of adipogenesis and modulator of fat cell function. Cell 99: 239-242
35. Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147-1156
36. Hu E, Tontonoz P, Spiegelman BM (1995) Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBP. Proc Natl Acad Sci USA 92: 9856-9860
37. Berger J, Leibowitz MD, Doebber TW et al. (1999) Novel peroxisome proliferator-activated receptor (PPAR) γ and PPAR δ ligands produce distinct biological effects. J Biol Chem 274: 6718-6725
38. Fukui Y, Masui S, Osada S, Umesono K, Motojima K (2000) A new thiazolidinedione, NC-2100, which is a weak PPAR-γ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 49: 759-767
39. Reginato MJ, Bailey ST, Krakow SL et al. (1998) A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 273: 32679-32684
40. Tafuri SR (1996) Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology 137: 4706-4712
41. Adams M, Montague CT, Prins JB et al. (1997) Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100: 3149-3153
42. Sottile V, Seuwen K (2000) Bone morphogenic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone). FEBS Lett 475: 201-204
43. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83: 803-812
44. Teboul L, Gaillard D, Staccini L, Inadera H, Amri E-Z, Grimaldi PA (1995) Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. J Biol Chem 270: 28183-28187
45. Sandouk T, Reda D, Hofmann C (1993) Antidiabetic agent pioglitazone enhances adipocyte differentiation of 3T3-F442A cells. Am J Physiol 264: C1600-C1608
46. Gimble JM, Robinson CE, Wu X et al. (1996) Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 50: 1087-1094
47. Wu Z, Xie Y, Morrison RF, Bucher NL, Farmer SR (1998) PPARγ induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPα during the conversion of 3T3 fibroblasts into adipocytes. J Clin Invest 101: 22-32
48. Digby JE, Montague CT, Sewter CP et al. (1998) Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 47: 138-141
49. Paulik MA, Lenhard JM (1997) Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells. Cell Tissue Res 290: 79-87
50. Strobel A, Siquier K, Zilberfarb V, Strosberg AD, Issad T (1999) Effect of thiazolidinediones on expression of UCP2 and adipocyte markers in human PAZ6 adipocytes. Diabetologia 42: 527-533
51. Schoonjans K, Staels B, Auwerx J (1996) The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93-109
52. Rosen ED, Spiegelman BM (2001) PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734
53. Spiegelman BM (1998) PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514
54. Auwerx J (1999) PPARγ, the ultimate thrifty gene. Diabetologia 42: 1033-1049
55. Barak Y, Nelson MC, Ong ES et al. (1999) PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 4: 585-595
56. Rosen ED, Sarraf P, Troy AE et al. (1999) PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4: 611-617
57. Hallakou S, Doaré L, Foufelle F et al. (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46: 1393-1399
58. De Vos P, Lefebvre AM, Miller SG et al. (1996) Thiazolidinediones repressob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. J Clin Invest 98: 1004-1009
59. Schwartz S, Raskin P, Fonseca V, Graveline JF, for the troglitazone and exogenous insulin study group (1998) Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 338: 861-866
60. Okuno A, Tamemoto H, Tobe K et al. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101: 1354-1361
61. Breider MA, Gough AW, Haskins JR, Sobocinski G, Iglesia FA de la (1999) Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol Pathol 27: 545-552
62. Akazawa S, Kawasaki E, Sun F, Eguchi K, Ito M (2000) Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 23: 1067-1071
63. Mori Y, Yokoyama J, Murakawa Y et al. (1999) Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22: 908-912
64. Katoh S, Hata S, Matsushima M et al. (2001) Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy - a randomized controlled trial. Metabolism 50: 414-417
65. Kubota N, Terauchi Y, Miki H et al. (1999) PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4: 597-609
66. Deeb SS, Fajas L, Nemoto M et al. (1998) A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20: 284-287
67. Barroso I, Gurnell M, Crowley VEF et al. (1999) Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-883
68. Bar-Tana J (2001) Peroxisome-proliferator-activated receptor gamma (PPARγ) activation and its consequences in humans. Toxicol Lett 120: 9-19
69. Berger J, Bailey P, Biswas C et al. (1996) Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137: 4189-4195
70. Arakawa K, Ishihara T, Aoto M, Inamusa M, Saito A, Ikezawa K (1998) Actions of novel antidiabetic thiazolidinedione, T-174, in animal models of non-insulin-dependent diabetes mellitus (NIDDM) and in cultured muscle cells. Br J Pharmacol 125: 429-436
71. Willson TM, Cobb JE, Cowan DJ et al. (1996) The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668
72. Murakami K, Tobe K, Ide T et al. (1998) A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPARγ. Effect of PPARα activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 47: 1841-1847
73. Shibata T, Matsui K, Nagao K, Shinaki H, Yonemori F, Wakitani K (1999) Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol 364: 211-219
74. Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, Wakitani K (2000) Effects of peroxisome proliferator-activated receptor-α and -γ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 130: 495-504
75. Brown KK, Henke BR, Blanchard SG et al. (1999) A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48: 1415-1424
76. Cobb JE, Henke BR, Blanchard SG (2000) Discovery and in vitro characterization of the novel, tyrosine-based, non-thiazolidinedione PPARγ agonist GI262570. Diabetologia 43 [Suppl 1]: A189 (Abstract)
77. Harrington WW, Hashim M, Faison W, Oliver W, Binz J, Brown KK (2000) Antidiabetic efficacy of GI262570 in rodent models of Type II diabetes. Diabetologia 43 [Suppl 1]: A67 (Abstract)
78. Mukherjee R, Davies PJA, Crombie DL et al. (1997) Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386: 407-410
79. Lenhard JM, Lancaster ME, Paulik MA et al. (1999) The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia 42: 545-554
80. Vikramadithyan RK, Chakrabarti R, Misra P et al. (2000) Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Metabolism 49: 1417-1424
81. Shimaya A, Kurosaki E, Nakano R, Hirayama R, Shibasaki M, Shikama H (2000) The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism 49: 411-417
82. Upton R, Widdowson PS, Ishii S, Tanaka H, Williams G (1998) Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555. Br J Pharmacol 125: 1708-1714
83. Nugent C, Prins JB, Whitehead JP et al. (2001) Potentiation of glucose uptake in 3T3-L1 adipocytes by PPARγ agonists is maintained in cells expressing a PPARγ dominant-negative mutant: evidence for selectivity in the downstream responses to PPARγ activation. Mol Endocrinol 15: 1729-1738
84. Burger HG (2000) Selective oestrogen receptor modulators. Horm Res 53 [Suppl 3]: 25-29
85. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y, Kato S (2000) Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators. J Biol Chem 275: 33201-33204
86. Camp HS, Li O, Wise SC et al. (2000) Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes 49: 539-547
87. Burant CF, Sreenan S, Hirano K et al. (1997) Troglitazone action is independent of adipose tissue. J Clin Invest 100: 2900-2908
88. Arioglu E, Duncan-Morin J, Sebring N et al. (2000) Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 133: 263-274
89. Chao L, Marcus-Samuels B, Mason MM et al. (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106: 1221-1228
90. Kahn CR, Chen L, Cohen SE (2000) Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106: 1305-1307
91. Stevenson RW, Hutson NJ, Krupp MN et al. (1990) Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes 39: 1218-1227
92. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI (2000) Mechanism of troglitazone action in type 2 diabetes. Diabetes 49: 827-831
93. Roden M, Krssak M, Stingl H et al. (1999) Rapid impairment of skeletal muscle glucose transport/phosphorylation by free fatty acids in humans. Diabetes 48: 358-364
94. Waldhäusl WK, Roden M (2000) The effects of free fatty acids on glucose transport and phosphorylation in human skeletal muscle. Curr Opin Endocrinol Diabetes 7: 211-216
95. Boden G (1996) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 45: 3-10
96. Thompson AL, Lim-Fraser MY, Kraegen EW, Cooney GJ (2000) Effects of individual fatty acids on glucose uptake and glycogen synthesis in soleus muscle in vitro. Am J Physiol: E577-E584
97. Yamauchi T, Kamon J, Waki H et al. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 276: 41245-41254
98. Yamauchi T, Kamon J, Waki H et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946
99. Maeda N, Takahashi M, Funahashi T et al. (2001) PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099
100. Hofmann C, Lorenz K, Braithwaite SS et al. (1994) Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134: 264-270
101. Kallen CB, Lazar MA (1996) Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 93: 5793-5796
102. Steppan CM, Bailey ST, Bhat S et al. (2001) The hormone resistin links obesity to diabetes. Nature 409: 307-312
103. Way JM, Görgün CZ, Tong Q et al. (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists. J Biol Chem 276: 25651-25653
104. Chua SC, Chung WK, Wu-Peng XS et al. (1996) Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271: 994-996
105. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM (1994) Positional cloning of the mouseobese gene and its human homologue. Nature 372: 425-432
106. Begum N, Ragolia L (1996) Effect of tumor necrosis factor-α on insulin action in cultured skeletal muscle cells. Endocrinology 137: 2441-2446
107. Fürnsinn C, Neschen S, Wagner O, Roden M, Bisschop M, Waldhäusl W (1997) Acute and chronic exposure to tumor necrosis factor-α fails to affect insulin-stimulated glucose metabolism of isolated rat soleus muscle. Endocrinology 138: 2674-2679
108. Nolte LA, Hansen P, Chen MM, Schluter JM, Gulve EA, Holloszy JO (1998) Short-term exposure to tumor necrosis factor-α does not affect insulin-stimulated glucose uptake in skeletal muscle. Diabetes 47: 721-726
109. Berg AH, Combs TB, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7: 947-953
110. Fruebis J, Tsao T-S, Javorschi S et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005-2010
111. Fürnsinn C, Neschen S, Noe C et al. (1997) Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazonein vitro. B J Pharmacol 122: 1367-1374
112. 2 production from glucose and palmitate in isolated rat skeletal muscle. J Pharmacol Exp Ther 293: 487-493
113. Brunmair B, Gras F, Neschen S et al. (2001) Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-γ-mediated changes in gene expression. Diabetes 50: 2309-2315
114. Kausch C, Krützfeldt J, Witke A et al. (2000) Effects of troglitazone on cellular differentiation, insulin signaling, and muscle glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun 280: 664-674
115. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR (1998) Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects. J Clin Endocrinol Metab 83: 1636-1643
116. Cha BS, Ciaraldi TP, Carter L et al. (2001) Peroxisome proliferator-activated receptor (PPAR) γ and retinoid X receptor (RXR) agonists have complemetary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 44: 444-452
117. Ciaraldi TP, Huber-Knudsen K, Hickman M, Olefsky JM (1995) Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents. Metabolism 44: 976-982
118. El-Kebbi IM, Roser S, Pollet RJ (1994) Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism 43: 953-958
119. Yonemitsu S, Nishimura H, Shintani M et al. (2001) Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 50: 1093-1101
120. Okuno A, Ikeda K, Shiota M et al. (1997) Acute effect of troglitazone on glucose metabolism in the absence or presence of insulin in perfused rat hindlimb. Metabolism 46: 716-721
121. Brunmair B, Gras F, Lest A, Roden M, Waldhäusl W, Fürnsinn C (2001) Insulin sensitization by prolonged troglitazone exposure of rat skeletal muscle in vitro. Diabetologia 44 [Suppl 1]: A202 (Abstract)
122. Shibukawa A, Sawada T, Nakao C, Izumi T, Nakagawa T (1995) High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma. J Chromatogr A 697: 337-343
123. Liu LS, Tanaka H, Ishii S, Eckel J (1998) The new antidiabetic drug MCC-555 acutely sensitizes insulin signalling in isolated cardiomyocytes. Endocrinology 139: 4531-4539
124. Kreutter DK, Andrews KM, Gibbs EM, Hutson NJ, Stevenson RW (1990) Insulin-like activity of new antidiabetic agent CP 68722 in 3T3-L1 adipocytes. Diabetes 39: 1414-1419
125. Fürnsinn C, Englisch R, Ebner K, Nowotny P, Vogl C, Waldhäusl W (1996) Insulin-like vs. non-insulin-like stimulation of glucose metabolism by vanadium, tungsten, and selenium compounds in rat muscle. Life Sci 59: 1989-2000
126. Ihlemann J, Plough T, Hellsten Y, Galbo H (2000) Effects of stimulation frequency on contraction-induced glucose transport in rat skeletal muscle. Am J Physiol 279: E862-E867
127. Brunmair B, Neschen S, Gras F et al. (2000) Metabolic response to anisoosmolarity of rat skeletal muscle in vitro. Horm Metab Res 32: 251-255 (Erratum in: Horm Metab Res 32: 440)
128. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects trough inhibition of complex 1 of the mitochiondrial respiratory chain. Biochem J 348: 607-614
129. El-Mir M-Y, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223-228
130. Lee MK, Olefsky JM (1995) Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism 44: 1166-1169
131. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA (1990) In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39: 1056-1062
132. Loviscach M, Rehmann N, Carter L et al. (2000) Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia 43: 304-311
133. Raman P, Foster SE, Stokes MC, Strenge JK, Judd RL (1998) Effect of troglitazone (Rezulin) on fructose 2,6-bisphosphate concentration and glucose metabolism in isolated rat hepatocytes. Life Sci 62: 89-94
134. Raman P, Judd RL (2000) Role of glucose and insulin in thiazolidinedione-induced alterations in hepatic gluconeogenesis. Eur J Pharmacol 409: 19-29
135. Adams MD, Raman P, Judd RL (1998) Comparative effects of troglitazone and glyburide on gluconeogenesis and glycolysis in the isolated perfused rat liver. Biochem Pharmacol 55: 1915-1920
136. Nishimura Y, Inoue Y, Takeuchi H, Oka Y (1997) Acute effects of pioglitazone on glucose metabolism in perfused rat liver. Acta Diabetol 34: 206-210
137. Fulgencio J-P, Kohl C, Girard J, Pégorier J-P (1996) Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45: 1556-1562
138. Preininger K, Stingl H, Englisch R et al. (1999) Acute troglitazone action in perfused rat liver. Br J Pharmacol 126: 372-378
139. Pugazhenthi S, Khandelwal RL (1998) Insulin action on protein phosphatase-1 activation is enhanced by the antidiabetic agent pioglitazone in cultured diabetic hepatocytes. Mol Cell Biochem 182: 185-191
140. Davies GF, Khandelwal RL, Wu L, Juurlink BH, Roesler WJ (2001) Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-γ (PPARγ)-independent, antioxidant-related mechanism. Biochem Pharmacol 62: 1071-1079
141. Memon RA, Tecott LH, Nonogaki K et al. (2000) Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141: 4021-4031
142. Bedoucha M, Atzpodien E, Boelsterli UA (2001) Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 35: 17-23
143. Weinstock RS, Murray FT, Diani A, Sangani GA, Wachowski MB, Messina JL (1996) Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. Pharmacology 54: 169-178
144. Oakes ND, Thalën PG, Jacinto SM, Ljung B (2001) Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50: 1158-1165
145. Jia DM, Tabaru A, Akiyama T, Abe S, Otsumi M (2000) Troglitazone prevents fatty changes of the liver in obese diabetic rats. J Gastroenterol Hepatol 15: 1183-1191
146. Sakamoto J, Kimura H, Moriyama S et al. (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278: 704-711
147. Peters JM, Hennuyer N, Staels B et al. (1997) Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor-α deficient mice. J Biol Chem 272: 27307-27312
148. Matsui H, Okumura K, Kawakami K, Hibino M, Toki Y, Ito T (1997) Improved insulin sensitivity by bezafibrate in rats. Relationship to fatty acid composition of skeletal-muscle triglycerides. Diabetes 46: 348-353
149. Kobayashi M, Shigeta Y, Hirata Y et al. (1988) Improvement of glucose tolerance in NIDDM by clofibrate. Diabetes Care 11: 495-499
150. Guerre-Millo M, Gervois P, Raspé E et al. (2000) Peroxisome-proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642
151. Ide T, Nakazawa T, Mochizuki T, Murakami K (2000) Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. Metabolism 49: 521-525
152. Jones SA, Moore LB, Shenk JL et al. (2000) The pregnane X receptor: A promicous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14: 27-39
153. Morita H, Oki Y, Ito T, Ohishi H, Suzuki S, Nakamura H (2001) Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM. Diabetes Care 24: 788-789